.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
McKinsey
Argus Health
Colorcon
Fish and Richardson
Healthtrust
QuintilesIMS
Deloitte
Dow
Daiichi Sankyo

Generated: July 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,488,827

« Back to Dashboard

Claims for Patent: 7,488,827

Title:Muscarinic acetylcholine receptor antagonists
Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Inventor(s): Laine; Damane I. (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:11/774,867
Patent Claims: 1. The compound which is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicycl- o[2.2.2]octane bromide.

2. A pharmaceutical composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicycl- o[2.2.2]octane bromide and a pharmaceutically acceptable carrier thereof.

3. The compound ##STR00047## wherein X is a pharmaceutically acceptable anion.

4. The compound according to claim 3 wherein the pharmaceutically acceptable anion is chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate.

5. The compound according to claim 3 wherein the pharmaceutically acceptable anion is bromide.

6. The compound according to claim 3 wherein the pharmaceutically acceptable anion is iodide.

7. A pharmaceutical composition comprising the compound ##STR00048## wherein X is a pharmaceutically acceptable anion, and a pharmaceutically acceptable carrier thereof.

8. The composition according to claim 7 wherein the pharmaceutically acceptable anion is chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate.

9. The composition according to claim 7 wherein the pharmaceutically acceptable anion is bromide.

10. The composition according to claim 7 wherein the pharmaceutically acceptable anion is iodide.

11. A pharmaceutical composition according to claim 2 in a form suitable for administration by oral or nasal inhalation.

12. A pharmaceutical composition according to claim 11 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, multi-dose dry powder inhaler, or a metered dose inhaler.

13. A pharmaceutical composition according to claim 2 which is a dry powder composition.

14. A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable carrier is lactose.

15. A pharmaceutical composition according to claim 7 in a form suitable for administration by oral or nasal inhalation.

16. A pharmaceutical composition according to claim 15 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler.

17. A pharmaceutical composition according to claim 7 which is a dry powder composition.

18. A pharmaceutical composition according to claim 7 wherein the pharmaceutically acceptable carrier is lactose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Novartis
QuintilesIMS
Covington
Healthtrust
Daiichi Sankyo
Julphar
McKinsey
Cerilliant
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot